Eleclazine hydrochloride
CAS No. 1448754-43-5
Eleclazine hydrochloride ( GS-6615 hydrochloride )
产品货号. M11926 CAS No. 1448754-43-5
一种新型、强效、选择性的晚钠电流 (late INa) 抑制剂,用于治疗长 QT-3 综合征 (LQT-3)。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥1121 | 有现货 |
|
| 10MG | ¥1691 | 有现货 |
|
| 25MG | ¥2725 | 有现货 |
|
| 50MG | ¥3887 | 有现货 |
|
| 100MG | ¥5067 | 有现货 |
|
| 200MG | ¥6831 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ¥1131 | 有现货 |
|
生物学信息
-
产品名称Eleclazine hydrochloride
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述一种新型、强效、选择性的晚钠电流 (late INa) 抑制剂,用于治疗长 QT-3 综合征 (LQT-3)。
-
产品描述A novel, potent, and selective inhibitor of Late sodium current (late INa) for treatment of long QT-3 syndrome (LQT-3), hypertrophic cardiomyopathy (HCM), and ventricular tachycardia–ventricular fibrillation (VT–VF); 42 times more potent than Ranolazine in reducing ischemic burden in vivo (EC50=190 nM).Heart Arrhythmia Phase 3 Clinical(In Vitro):Eleclazine inhibits sodium current in hiPSC-derived cardiomyocytes with an IC50 of 2.5 μM.(In Vivo):Eleclazine (0.3 and 0.9 mg/kg; IV; infused over 15 minutes) reduces the incidence of epinephrine-induced ventricular premature beats and couplets, and shortens ventricular QT and atrial PTa intervals.
-
体外实验Eleclazine inhibits sodium current in hiPSC-derived cardiomyocytes with an IC50 of 2.5 μM.
-
体内实验Eleclazine (0.3 and 0.9 mg/kg; IV; infused over 15 minutes) reduces the incidence of epinephrine-induced ventricular premature beats and couplets, and shortens ventricular QT and atrial PTa intervals. Animal Model:Male Yorkshire pigs (35.20 ± 0.46 kg; injected with epinephrine via a jugular vein)Dosage:0.3 and 0.9 mg/kg Administration:IV; infused over 15 minutes Result:Reduced the incidence of epinephrine-induced ventricular premature beats and couplets by 51% (from 31.3 ± 1.91 to 15.2 ± 5.08 episodes; P = 0.038) and the incidence of 3- to 7-beat ventricular tachycardia (VT) by 56% (from 10.8 ± 3.45 to 4.7 ± 3.12 episodes; P = 0.004).Shortened ventricular QT and atrial PTa intervals by 7%, and reduced atrial repolarization alternans and heterogeneity without attenuation of the inotropic response to catecholamine.
-
同义词GS-6615 hydrochloride
-
通路Membrane Transporter/Ion Channel
-
靶点Sodium Channel
-
受体Sodium Channel
-
研究领域Cardiovascular Disease
-
适应症Heart Arrhythmia
化学信息
-
CAS Number1448754-43-5
-
分子量451.8262
-
分子式C21H17ClF3N3O3
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESO=C1N(CC2=NC=CC=N2)CCOC3=CC=C(C4=CC=C(OC(F)(F)F)C=C4)C=C13.[H]Cl
-
化学全称1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4-(trifluoromethoxy)phenyl]-, hydrochloride (1:1)
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Zablocki JA, et al. J. Med. Chem., 2016, 59 (19), pp 9005–90172. Fuller H, et al. Heart Rhythm. 2016 Aug;13(8):1679-86.
3. Bacic D, et al. Heart Rhythm. 2017 Mar;14(3):448-454.
产品手册
关联产品
-
Phenytoin
Phenytoin (5,5-Diphenylhydantoin) 是一种有效的电压门控 Na+ 通道 (VGSCs) 阻滞剂。Phenytoin 具有抗癫痫活性,也可减少小鼠乳腺肿瘤的生长和转移。
-
BI-9627
BI-9627 是一种钠氢交换异构体 1 (NHE1) 抑制剂,在细胞内 pH 恢复 (pHi) 和人血小板溶胀试验中 IC50 值为 6 和 31 nM。BI-9627 对 NHE2 的选择性大于 30 倍,对 NHE3 没有明显的抑制活性。BI-9627 表现出较低的 DDI (活性分子-活性分子相互作用) 潜力,在大鼠和犬体内良好的药代动力学,在离体心脏缺血-再灌注损伤模型中表现出显著的活性。
-
Ambroxol hydrochlori...
Ambroxol HCl 是神经元 Na+ 通道的有效抑制剂,抑制 TTX 抗性 Na+ 电流,IC50 为 35.2 μM,对于强直和相位阻滞,IC50 为 35.2 μM,IC50 为 22.5 μM。
021-51111890
购物车()
sales@molnova.cn

